| 王敏,马佼,刘李乙,张春银.放射性标记Pentixafor/Pentixather用于靶向诊疗肿瘤进展[J].中国医学影像技术,2023,39(5):785~788 |
| 放射性标记Pentixafor/Pentixather用于靶向诊疗肿瘤进展 |
| Progresses of radiolabeled Pentixafor/Pentixather applied in targeted diagnosis and treatment of tumors |
| 投稿时间：2022-09-19 修订日期：2023-03-16 |
| DOI：10.13929/j.issn.1003-3289.2023.05.034 |
| 中文关键词: 肿瘤 受体,趋化因子 分子靶向治疗 |
| 英文关键词:neoplasms receptors, chemokine molecular targeted therapy |
| 基金项目: |
|
| 摘要点击次数: 1022 |
| 全文下载次数: 447 |
| 中文摘要: |
| 肿瘤细胞表面多过度表达趋化因子受体4(CXCR4),后者在肿瘤发生、发展和转移等各环节中具有重要作用,为靶向诊疗肿瘤的重要靶点。Pentixafor是由基质细胞衍生因子-1合成的环五肽类似物,为CXCR4配体,可用于合成放射性共轭物68Ga-Pentixafor,而Pentixather为其治疗用化合物。近年来,放射性标记Pentixafor/Pentixather在诊断和治疗肿瘤方面展现出重要作用。本文就放射性标记Pentixafor/Pentixather在靶向诊疗肿瘤中的应用进展进行综述。 |
| 英文摘要: |
| Chemokine receptor 4 (CXCR4) is overexpressed on the surface of most tumor cells, playing an important role in the occurrence, development and metastasis of tumors, hence being important for targeted diagnosis and treatment of tumors. Pentixafor is a cyclic pentapeptide analogue synthesized by stromal cell-derived factor 1, also is a ligand of CXCR4, which can be used to synthesize radioactive conjugate 68Ga-Pentixafor. Pentixather is the corresponding therapeutic compound of 68Ga-Pentixafor. In recent years, radiolabeled Pentixafor/Pentixather had played an important role in diagnosis and treatment of tumors. The progresses of radiolabeled Pentixafor/Pentixather applied in targeted diagnosis and treatment of tumors were reviewed in this article. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
